Role of HLA in Hematopoietic Stem Cell Transplantation and Other Donor Selection Criterion (21EL-670)

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, September 1, 2021 - On-Demand Available
Program Number: 21EL-670

  • Educational Track: Scientific
  • Topics: Cellular Therapy, Chimerism, Complications, Cord Blood, Donation, Immunosuppression, Patient Transfusion, Relapse, Therapeutic Apheresis, Transfusion Safety
  • Intended Audience: Directors, Donor Recruitment Staff, Facilities that perform molecular testing, Laboratory Staff, Managers/Supervisors, Medical Directors, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists
  • Teaching Level: Advanced, Intermediate
  • Director: Indira Guleria, PhD Diplomate (ABHI), Associate Director, HLA Tissue Typing Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
    Moderator: Thomas Spitzer, MD, Director Emeritus, Bone Marrow Transplant Program, Walter Bauer Firm Chief, Massachusetts General Hospital, Professor of Medicine, Harvard Medical School, Boston, MA

    • Indira Guleria, PhD Diplomate (ABHI), Associate Director, HLA Tissue Typing Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
    • Mahasweta Gooptu, MD, Attending Physician, Adult Stem-Cell Transplantation, Dana-Farber Cancer Institute; Assistant Professor, Harvard Medical School, Boston, MA
  • Program Description

    Hematopoietic stem cells are self renewing, multipotent cells with malignancies of these cells being fatal and their replacement with normal stem cells is often required to cure disease. Human Leukocyte antigens (HLA) antigens are histocompatibility antigens and disparity in HLA antigens between stem cell transplant donor and recipients is one of the most important factors influencing transplant outcomes such as relapse, graft failure and graft vs host disease. Donor selection criteria including HLA matching, sensitization to HLA in selecting mismatch and role of non-HLA components in selection process for stem cell transplants will be discussed. Concept of “permissive mismatch” will be covered as well. This program will review the available approaches, and the benefits and limitations of each of the post-transplant monitoring methodologies the HLA labs utilize to measure donor engraftment.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Describe the diseases treated with transplantation of hematopoietic progenitor cells with view to discuss the pros and cons of different sources of stem cells.
    • Discuss donor selection criteria and the donor search process and impact of donor and recipient HLA disparity on graft outcomes.
    • Describe the assays for HLA typing of patient and potential donors, screening for antibodies to HLA and post-transplant chimerism monitoring to determine engraftment of donor cells.


    Please note: If you registered for the live eCast you do not need to register for the on-demand eCast (access to the on-demand eCast was included with the live eCast registration. Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time you will receive access to the on-demand eCast when it is available.

    Single Viewer Register
    Group Viewing Register

    Continuing Education Credit

    AABB designates both the live and on-demand version of this eCast each to be eligible for 1.5 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.


    Mahasweta Gooptu, MDMahasweta Gooptu, MD attended medical school at Kolkata Medical College in India, followed by a residency at Albert Einstein Medical Center and fellowship at Thomas Jefferson University in Philadelphia. She completed an advanced fellowship in adult hematopoietic stem cell transplantation at Dana-Farber Cancer Institute and is currently an attending physician in the adult SCT division. Dr. Gooptu's research interests include relapse prevention post-transplant, ,haploidentical transplantation and the role of post-transplant cyclophosphamide in GVHD prophylaxis and post-transplantation immune reconstitution.

    Indira Guleria, MDIndira Guleria, PhD is Associate Director of HLA laboratory at Brigham and Women’s Hospital and is Assistant Professor of Medicine at Harvard Medical School. Dr. Guleria obtained her PhD in Immunology from National Institute of Immunology in India followed by postdoctoral fellowship at Albert Einstein College of Medicine. Dr. Guleria’s primary research involves studying the mechanisms of transplant tolerance with a focus on the role of various costimulatory molecules in the rejection of, or tolerance to allograft. She has also made original and significant contributions to the field of immunobiology of solid and stem cell transplantation and has been part of the multi-disciplinary team facilitating stem cell transplants at the Dana Farber Cancer Institute. In addition to her research and administrative responsibilities, Dr. Guleria has been a leader in providing education to fellows, residents, and faculty and has helped develop professional educational programs and learning tools such as regular lectures, simple and complex case presentations, boot camps, and wet workshops to enhance knowledge, skill, abilities, and competency of the participants.

    Thomas Spitzer, MDThomas R. Spitzer, MD is Medical and Laboratory Director of the Cellular Therapy and Transplantation Laboratory and Emeritus Director of the Bone Marrow Transplant Program, at the Massachusetts General Hospital and is Professor of Medicine at Harvard Medical School. He is also Walter Bauer Firm Chief in the Department of Medicine. Dr. Spitzer received his Bachelor of Science degree in Biology from Bucknell University and his M.D. from the University of Rochester School of Medicine. He completed his internship and residency in Internal Medicine at New York Hospital-Cornell Medical Center and Memorial-Sloan Kettering Cancer Center, and his Hematology-Oncology fellowship at Case Western Reserve University. His primary research interests have included the development of novel strategies for performing hematopoietic cell transplants across HLA barriers for hematologic malignancies and for inducing specific tolerance for organ transplantation by performing combined bone marrow and kidney transplants. The cellular therapy lab that he directs has provided all the products for hematopoietic cell transplantation at MGH and is currently involved with many novel immune effector cellular therapy trials. He has assumed leadership roles in AABB, including being elected as Chair of the Cellular Therapy Section Coordinating Committee and serving as a member of the Board of Directors. He is a devoted teacher of medical students and residents in his Firm Chief role, and he has been the recipient of teaching awards for his contributions to medical education.